What Is SS-31 Peptide? Elamipretide Explained

SS-31 peptide (sometimes written SS 31 peptide), also known as elamipretide, is a synthetic mitochondria-targeted tetrapeptide that binds to cardiolipin on the inner mitochondrial membrane and supports cellular energy production. It is an investigational compound, not an FDA-approved drug, and it is sold only as a research chemical for laboratory use. Researchers studying what does ss 31 peptide do are focused on conditions linked to mitochondrial dysfunction, including Barth syndrome, primary mitochondrial myopathy, and dry age-related macular degeneration.

What Is SS-31 Peptide and How Does It Work?

SS-31 is a short chain of four amino acids: D-arginine, dimethyltyrosine, lysine, and phenylalanine. Scientists Eugene Szeto and Hazel Szeto developed the molecule, which is why it is sometimes called a Szeto-Schiller peptide. The SS in its name comes from their surnames.

The peptide is cell-permeable and concentrates in mitochondria. Once inside, SS-31 binds cardiolipin, a phospholipid found in the inner mitochondrial membrane. This binding helps stabilize the membrane structure, reduces reactive oxygen species, and improves ATP production.

A simple way to describe the mechanism is this: SS-31 acts like a support beam for the mitochondria inner membrane. When cardiolipin is protected, the mitochondria can produce energy more efficiently and release fewer damaging free radicals.

Key molecular facts

• Chemical class: Synthetic tetrapeptide
• Sequence: D-Arg-Dmt-Lys-Phe-NH2
• Target: Inner mitochondrial membrane cardiolipin
• Common research name: Elamipretide
• Route in trials: Subcutaneous injection

What Is SS-31 Peptide Used For in Medical Research?

Scientists investigating what is ss-31 peptide used for have studied it in several small clinical trials. Most of these studies focus on diseases where mitochondria do not produce enough energy or where oxidative stress damages tissues.

Research areas have included:

• Barth syndrome, a rare genetic disorder that affects mitochondrial function
• Primary mitochondrial myopathy, which causes muscle weakness and exercise intolerance
• Dry age-related macular degeneration, a leading cause of vision loss
• Heart failure with preserved ejection fraction
• Acute kidney injury and other ischemia-reperfusion injuries
• Neurodegenerative conditions such as Parkinson disease

These are investigational uses. SS-31 peptide is not approved for treating any medical condition. Some trials have shown signals of benefit, while others have failed to meet their primary endpoints, so the evidence remains mixed.

SS-31 Peptide Benefits and Side Effects Reported in Studies

Any discussion of ss-31 peptide benefits and side effects should start with a clear caveat: most human data come from small, short-term trials. That makes it hard to draw firm conclusions about how well the peptide works or how safe it is over time.

In published research, potential benefits have included:

• Improved mitochondrial energy production in muscle and heart cells
• Reduced markers of oxidative stress
• Better exercise tolerance in some patients with mitochondrial myopathy
• Possible improvements in visual function in dry AMD studies

Reported ss-31 peptide side effects in clinical trials have generally been mild to moderate. The most common issues include:

• Injection site reactions, such as pain, redness, or swelling
• Headache
• Nausea
• Fatigue
• Dizziness

Serious adverse events have been rare in trials, but long-term safety data are limited. SS-31 peptide is not recommended for human use outside of a clinical trial.

How SS-31 Compares With Other Research Peptides

SS-31 is often discussed alongside other research peptides, but they have different mechanisms and research histories. If you are wondering what is bpc 157 peptide, it is a synthetic peptide studied for tissue repair and gut health, not mitochondrial function.

The table below compares SS-31 with a few other peptides commonly sold as research chemicals.

Each of these peptides has its own risk profile and legal status. None of them are FDA-approved for general human use, and buying them from online vendors carries significant quality and safety risks.

Legal and Safety Status of SS-31 Peptide

SS-31 peptide is not FDA-approved for human use in the United States. As of 2025, elamipretide remains an investigational drug, and the FDA has not granted it marketing approval for any indication.

Because of that status, SS-31 is legally sold only as a research chemical. Products labeled for research use only are not intended for human consumption, and they are not regulated for purity, sterility, or accurate dosing.

If you are considering any peptide for a health condition, talk with a licensed healthcare professional first. Self-administering unapproved peptides can cause harm, and it may interact with other treatments you are receiving.

Key Takeaways

• SS-31 peptide is a mitochondria-targeted tetrapeptide also known as elamipretide.
• SS-31 peptide is not FDA-approved for any human use in the United States.
• Research has focused on mitochondrial diseases, heart failure, and dry AMD, but results are mixed.
• Reported side effects in trials are usually mild, but long-term safety is unknown.
• SS-31 is sold as a research chemical and should not be used without medical supervision.